I don't call the contest a pump at all. I'm pretty sure everyone understands that the contest was contigent upon the trial successfully meeting its primary outcome and also acknowledge what will happen to the share price if the primary outcome is missed.

It is not stating what the company is worth now, but projecting what the company could be worth with a first-in-class small molecule bromodomain-2 selective BET inhibitor that has no competition on the horizon and could not only achieve an unprecedented %RRR based on trial design but could also be the first therapy to prove any %RRR in the high risk diabetic recent ACS population. Add on to that the renal and cognition sub-studies. These projections are also in line the market cap elevations of Amarin, a contemporary company achieving CVOT success. 

BDAZ